TScan Therapeutics Reaches Agreement with FDA on Pivotal Study Design for TSC-101 and Announces Strategic Prioritization to Advance TSC-101 and Extend Cash Runway into H2 2027

Stock Information for TScan Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About TScan Therapeutics Inc.

Blood Cancer Therapeutics Reach Critical Commercial and Clinical Inflection Points
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA(TM) Phase 1 Trial and Future Market Opportunities
TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
TScan Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025
TScan Therapeutics to Participate in Upcoming Investor Conferences
TScan Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.